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A B S T R A C T
Thrombocytopenia is a well-known side effect following
intramuscular gold therapy in patients with rheumatoid
arthritis. Thrombocytopenia may occur at any time and it
can be irreversible and sometimes fatal despite cytotoxic
or immunosuppressive therapy.
We describe two patients who presented with haemorrhagic
diathesis on the day after the administration of auro-
thioglucose. The thrombocytopenia in these patients was
caused by aurothioglucose-induced antibody-mediated
platelet destruction. Both patients made an uneventful
recovery and the platelet count returned to normal within
several weeks without further treatment. Antibody-detecting
tests were repeated five years later and could not demon-
strate the presence of antibodies. Also after incubation
with aurothioglucose no antibodies could be demonstrated.
I N T R O D U C T I O N
Haematological abnormalities are well-known complications
following intramuscular gold therapy in patients with
rheumatoid arthritis1-3 with an incidence of 1 to 3% in
most series. The occurrence of thrombocytopenia during
gold therapy is unpredictable and may occur at any time
during treatment. Development of thrombocytopenia may
be insidious or acute and the cause can be diverse and
sometimes difficult to assess. Both bone marrow depression
and antibody-mediated platelet destruction have been
described.4-7 The course of thrombocytopenia can be
irreversible and sometimes fatal despite cytotoxic or
immunosuppressive therapy. Long-term follow-up after
thrombocytopenia caused by antibodies directed against
platelets in the presence of gold is unknown.
We studied the cause of thrombopenia in two patients who
presented on the day after the administration of
aurothioglucose with severe haemorrhagic diathesis.
C A S E  R E P O R T S
Patient 1
A 51-year-old woman was seen in our outpatient clinic
because of a seropositive, erosive and nodular rheumatoid
arthritis (RA) since 1991. After initial treatment with
sulphasalazine, intramuscular aurothioglucose was started at
100 mg weekly until a cumulative dose of 1000 mg.
While receiving a dose of 50 mg aurothioglucose once every
two weeks, to a cumulative dose of 1350 mg, she mentioned
that she was developing haematomas on the day after the
aurothioglucose injection. During outpatient follow-up no
haematomas and normal platelet counts (192-320 x 109/l)
were found on the day the aurothioglucose was given. Clinical
examination one day after the aurothioglucose injection
showed petechiae and haematomas and the platelet count
had fallen from 238 x 109/l to 6 x 109/l in two days.
Indomethacin, calcium and vitamin D were stopped and
prednisone 7.5 mg daily was continued. A bone marrow
biopsy showed normocellular bone marrow with normal
megakaryopoiesis. Immunoglobulin G (IgG) could be
demonstrated on the patient’s platelets by the direct platelet
immunofluorescence test and the ether-eluate made of the
patient’s own platelets reacted positively to donor platelets
(table 1). Also IgG was demonstrated on donor platelets
after incubating with the patient’s serum.8 No binding of
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immunoglobulin of the IgM class was observed on the
platelets.9 With no additional treatment her platelet count
gradually returned to normal in three weeks (figure 1) and
no further aurothioglucose was given.
Five years later all tests were repeated without aurothioglucose
and with four different aurothioglucose concentrations
(table 1).10-15 All tests showed no detectable IgG on donor
and patient’s platelets.
Table 1
Tests measuring antibodies against platelets of both
patients during five-year follow-up
TESTS PATIENT 1 PATIENT 2
Indirect PIFT during admission1 + +
Direct PIFT during admission2 + +
Ether-eluation test during admission3 + +
Indirect PIFT after five years - -
Indirect PIFT after five years - -
with aurothioglucose4
Direct PIFT after five years - -
Ether-eluation after five years - -
1 Indirect Platelet Immunoflourescence Test: incubation of donor platelets,
patient’s serum and anti-IgG-FITC. 2 Direct Platelet Immunoflourescence
Test: incubation of patient’s platelets and anti-IgG-FITC. 3 Eluate: reincuba-
tion of ether-eluated patient platelets to donor platelets and anti-IgG-FITC. 4
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Platelet count of patient 2 during aurothioglucose-induced
thrombocytopenia
dose of 1000 mg was reached. After a cumulative dose of
2700 mg, while receiving aurothioglucose injections of 25 mg
every third week, she mentioned that haematomas had
started to develop the day after the aurothioglucose injection.
No skin abnormalities, however, were noticed during
outpatient follow-up and the platelet counts were repeatedly
normal (260-330 x 109/l) before the next injection. However,
the clinical examination three days after the injection
revealed petechiae and haematomas and the platelet count
had fallen from 280 x 109/l to 18 x 109/l. The bone marrow
biopsy showed normal megakaryopoiesis and normo-
cellularity. Immunofluorescence tests demonstrated IgG
on patient’s own platelets and on donor platelets after
incubating with patient’s serum. An eluate made from
patient’s platelets reacted positively with donor platelets
(table 1). No IgM antibodies could be demonstrated. auro-
thioglucose injections were stopped and without additional
treatment her platelet count returned to normal (figure 2).
Five years later all tests were repeated with serum alone and
with four different concentrations of aurothioglucose (table 1).
All tests showed no IgG on the patient’s platelets (direct
immunofluorescence test). Platelets from one of three
donors showed binding of IgG to platelets after incubation
with patient’s serum without aurothioglucose, probably
caused by HLA antibodies.
Patient 2
A 47-year-old woman was seen in our outpatient clinic
because of a seropositive and erosive RA since 1989. After
treatment with sulphasalazine, intramuscular aurothioglucose
was given at a dose of 50 mg weekly until a cumulative
D I S C U S S I O N
In patients with RA, thrombocytopenia can be caused by
decreased thrombopoiesis, increased platelet destruction
and platelet pooling. Increased platelet destruction is
regularly encountered, caused by autoantibody-mediated
destruction on the basis of concomitant diseases (e.g.
Felty’s syndrome) or medication. Gold, as has been
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described in several case reports,1 can cause thrombo-
cytopenia by bone marrow aplasia4,5 or antibody-mediated
platelet destruction.6,7 Gold-induced aplasia is often
refractory to treatment. Most patients die of septic shock
before or after receiving immunosuppressive or cyto-
reductive therapy or even bone marrow transplantation.4,5
Gold-induced antibody-mediated platelet destruction
has been described by several authors in case reports or
small case series.2-5 Some studies showed HLA-DR3
positivity in 68 to 100% (normal prevalence 23%) of the
patients.3,16,17
The positive direct and indirect platelet immunofluorescence
tests (positive tests to donor and patient platelets together
with positive eluate reactions) can point to antibodies
directed against platelet-specific antigens (e.g. idiopathic
thrombocytopenia, Aldomet), against hidden antigens
exposed in the presence of aurothioglucose (as seen in EDTA-
dependent thrombocytopenia), or against aurothioglucose
itself, the platelet being destructed by the antibody-antigen
complex as an innocent bystander. The positive reaction of
the eluate with donor platelets, however, excluded antibody-
antigen complexes. The negative tests five years later with
incubation of aurothioglucose made the mechanism with a
hidden antigen unlikely. The tests point to a true auto-
antibody character of the antibodies directed against a
platelet-specific antigen, but induced by aurothioglucose. The
rapid resolution of the thrombocytopenia points to a
dose-dependent reaction of this autoantibody induction.
Gold administration can induce acute autoantibody-mediated
platelet destruction that is completely reversible without
treatment. Serious attention should be paid to patients
who report haemorrhagic diathesis in the days following
drug administration of any kind.
N O T E
Case histories and data were presented at the HOVON
continuous medical education day 2002 in Rotterdam.
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